16th Dec 2015- Mumbai, India: Bharatbook.com announces a report on “Forecast on China Recombinant Factor Ⅷ Market [2010-2019]”
The report Explained the points The Injecting clotting factor might be the only effective way to treat hemophilia. Recombinant factor (Kogenate Bayer) made by Bayer was approved by FDA and EMEA in 2000 to be used in many countries. In developed countries, the drugs for the prevention and treatment of hemophilia have a huge market.
Hemophilia is a hereditary bleeding disorder caused by a lack of clotting factor or though not rare, which affects mostly males. Hemophilia A (clotting factor deficiency) is the most common form of the disorder. The number of the cases of hemophilia is about over 0.4 million around the world while that in China is about 0.06-0.1 million, among which 80% lack clotting factor while over half are in severe conditions.Injecting clotting factor might be the only effective way to treat hemophilia. Recombinant factor (Kogenate Bayer) made by Bayer was approved by FDA and EMEA in 2000 to be used in many countries. In developed countries, the drugs for the prevention and treatment of hemophilia have a huge market. Apart from Bayer Schering, Baxter and Wyeth also make recombinant factor too.
After entering China, recombinant factor develops fast with annual sales value rising from less than CNY 6 million in 2009 to CNY 93.78 million in 2014 and CAGR reaching up to 76.8% during 2009-2014. Currently, recombinant factor in the Chinese market are all imported drugs. They mainly come from the following three companies: Baxter Bioscience Manufacturing (SW), Wyeth Farma S.A. (SP) and Bayer (the US), among which Bayer (the US) has the largest market share of 57.40% by sales value in 2014.
As hemophiliacs’ ability to pay for medical treatment keeps increasing due to economic development, the market size of recombinant factor in China is expected to keep expanding.
Readers can get at least the following information from this report:
-sales status of recombinant factor in China
-price of recombinant factor in Chinese market
-major manufacturers of recombinant factor in Chinese market
-share of dosage forms of recombinant factor in China
-market outlook of recombinant factor in China
The author suggests the following groups of people purchase this report:
-manufacturers of blood products
-investors/ research institutions interested in China blood products marketFor more information kindly visit: https://www.bharatbook.com/drugs-market-research-reports-667962/investigation-recombinant-china.html
About Bharat Book Bureau :
Bharat Book Bureau is the leading market research information provider for market research reports, company profiles, industry analysis, country reports, business reports, newsletters and online databases Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. We cover sectors starting from Aeronautics to Zoology.
In case the reports don’t match your requirement then we can do a specialized Custom Research for you. Our multifarious capabilities, cross-sector expertise and detailed knowledge of various markets, put us in a unique position to take up Custom Research demands of yourself.
Contact us at :
Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Follow us on Twitter: https://twitter.com/researchbook
Follow us on LinkedIn : http://www.linkedin.com/company/bharat-book-bureau
Our Blog : https://www.bharatbook.com/blog/
Bharat Book Bureau, the leading market research information aggregator provides market research reports, company profiles, country reports, newsletters, and online databases for the past twenty four years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Our market research reports help global companies to know different market before starting up business / expanding in different countries across the world.